Movement Alert｜Insilico Medicine Rises 5.37% in Regular Trading, Technical Rebound After Nearly 40% Monthly Decline Amid Sector Strength

Market Focus06-05

On June 5, Insilico Medicine rose 5.37% in regular trading, trading at 38.96 HKD/share, with trading volume of 33.69 million HKD.

On the news front, the stock experienced a technical rebound after suffering nearly 40% cumulative decline over the past month, driven by the collapse of Abu Dhabi secondary listing expectations and the approaching unlock of approximately 453 million shares (81.25% of total equity) on June 29. Short-term selling pressure appears to have been largely exhausted, triggering an oversold bounce.

Sector-wide strength in Life Sciences Tools and Services also provided a tailwind, with Pharmaron up 3.95%, WuXi AppTec up 2.75%, and WuXi Bio up 2.71%. On the fundamental side, the company's partnership with Eli Lilly worth up to USD 2.75 billion in AI-driven drug development and the establishment of a longevity committee continue to offer downside support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157665917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157665917","market":"us","top_or_hot":-1,"title":"Movement Alert｜Insilico Medicine Rises 5.37% in Regular Trading, Technical Rebound After Nearly 40% Monthly Decline Amid Sector Strength","media":"Market Focus","content":"<p><p>On June 5, Insilico Medicine rose 5.37% in regular trading, trading at 38.96 HKD/share, with trading volume of 33.69 million HKD.</p><p>On the news front, the stock experienced a technical rebound after suffering nearly 40% cumulative decline over the past month, driven by the collapse of Abu Dhabi secondary listing expectations and the approaching unlock of approximately 453 million shares (81.25% of total equity) on June 29. Short-term selling pressure appears to have been largely exhausted, triggering an oversold bounce.</p><p>Sector-wide strength in Life Sciences Tools and Services also provided a tailwind, with Pharmaron up 3.95%, WuXi AppTec up 2.75%, and WuXi Bio up 2.71%. On the fundamental side, the company's partnership with Eli Lilly worth up to USD 2.75 billion in AI-driven drug development and the establishment of a longevity committee continue to offer downside support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insilico Medicine Rises 5.37% in Regular Trading, Technical Rebound After Nearly 40% Monthly Decline Amid Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insilico Medicine Rises 5.37% in Regular Trading, Technical Rebound After Nearly 40% Monthly Decline Amid Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Insilico Medicine rose 5.37% in regular trading, trading at 38.96 HKD/share, with trading volume of 33.69 million HKD.</p><p>On the news front, the stock experienced a technical rebound after suffering nearly 40% cumulative decline over the past month, driven by the collapse of Abu Dhabi secondary listing expectations and the approaching unlock of approximately 453 million shares (81.25% of total equity) on June 29. Short-term selling pressure appears to have been largely exhausted, triggering an oversold bounce.</p><p>Sector-wide strength in Life Sciences Tools and Services also provided a tailwind, with Pharmaron up 3.95%, WuXi AppTec up 2.75%, and WuXi Bio up 2.71%. On the fundamental side, the company's partnership with Eli Lilly worth up to USD 2.75 billion in AI-driven drug development and the establishment of a longevity committee continue to offer downside support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1157665917","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157665917","pubTimestamp":1780624499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Insilico Medicine rose 5.37% in regular trading, trading at 38.96 HKD/share, with trading volume of 33.69 million HKD.On the news front, the stock experienced a technical rebound after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"动向提示|英矽智能常规盘涨5.37%板块走强下月跌近40%后技术性反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On June 5, Insilico Medicine rose 5.37% in regular trading, trading at 38.96 HKD/share, with trading volume of 33.69 million HKD.On the news front, the stock experienced a technical rebound after suffering nearly 40% cumulative decline over the past month, driven by the collapse of Abu Dhabi secondary listing expectations and the approaching unlock of approximately 453 million shares (81.25% of total equity) on June 29. Short-term selling pressure appears to have been largely exhausted, triggering an oversold bounce.Sector-wide strength in Life Sciences Tools and Services also provided a tailwind, with Pharmaron up 3.95%, WuXi AppTec up 2.75%, and WuXi Bio up 2.71%. On the fundamental side, the company's partnership with Eli Lilly worth up to USD 2.75 billion in AI-driven drug development and the establishment of a longevity committee continue to offer downside support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157665917","isCrawlerRequest":true}